Gotowe bibliografie tematyczne / Preclinical tumor models

Spis treści

  1. Artykuły w czasopismach
  2. Rozprawy doktorskie
  3. Książki
  4. Części książek
  5. Streszczenia konferencji

Gotowa bibliografia na temat „Preclinical tumor models”

Autor: Grafiati
Data publikacji: 8 czerwca 2024
Data aktualizacji: 31 lipca 2025

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Preclinical tumor models”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "Preclinical tumor models"

1

Varticovski, L., M. G. Hollingshead, M. R. Anver, et al. "Preclinical testing using tumors from genetically engineered mouse mammary models." Journal of Clinical Oncology 24, no. 18_suppl (2006): 10067. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.10067.

Pełny tekst źródła
Streszczenie:
10067 Background: Mouse models have been used extensively in preclinical testing of anticancer drugs. However, few of these models reflect the progression of human disease, and even fewer predict the performance of these drugs in clinical trials. Testing anticancer therapies in genetically engineered mouse (GEM) holds the promise of improving preclinical models and guiding the design of clinical trials. Unfortunately, the use of tumor-bearing GEM is hampered by the difficulty in simultaneously obtaining sufficient numbers of animals with the same stage of tumor development. The additional comp
Style APA, Harvard, Vancouver, ISO itp.
2

Klenner, Marbod, Pia Freidel, Mariella G. Filbin, and Alexander Beck. "DIPG-39. New preclinical models for Diffuse Midline Glioma." Neuro-Oncology 24, Supplement_1 (2022): i27. http://dx.doi.org/10.1093/neuonc/noac079.096.

Pełny tekst źródła
Streszczenie:
Abstract Malignant brain tumors are the leading cause of childhood death in Germany, with Diffuse Midline Glioma (DMG) being the most lethal of all paediatric brain tumors. Current treatment strategies are limited to irradiation which prolongs survival only by a few months. Preclinical studies have identified effective drug candidates, but translation into the clinic remains a major obstacle. It is known that interactions between tumor cells and components of the TME (tumor microenvironment), such as cell to cell contacts between malignant and non-malignant cells or secreted factors, can incre
Style APA, Harvard, Vancouver, ISO itp.
3

Llaguno-Munive, Monserrat, Wilberto Villalba-Abascal, Alejandro Avilés-Salas, and Patricia Garcia-Lopez. "Near-Infrared Fluorescence Imaging in Preclinical Models of Glioblastoma." Journal of Imaging 9, no. 10 (2023): 212. http://dx.doi.org/10.3390/jimaging9100212.

Pełny tekst źródła
Streszczenie:
Cancer is a public health problem requiring ongoing research to improve current treatments and discover novel therapies. More accurate imaging would facilitate such research. Near-infrared fluorescence has been developed as a non-invasive imaging technique capable of visualizing and measuring biological processes at the molecular level in living subjects. In this work, we evaluate the tumor activity in two preclinical glioblastoma models by using fluorochrome (IRDye 800CW) coupled to different molecules: tripeptide Arg-Gly-Asp (RGD), 2-amino-2-deoxy-D-glucose (2-DG), and polyethylene glycol (P
Style APA, Harvard, Vancouver, ISO itp.
4

Costa, Alice, Livia Gozzellino, Margherita Nannini, Annalisa Astolfi, Maria Abbondanza Pantaleo, and Gianandrea Pasquinelli. "Preclinical Models of Visceral Sarcomas." Biomolecules 13, no. 11 (2023): 1624. http://dx.doi.org/10.3390/biom13111624.

Pełny tekst źródła
Streszczenie:
Visceral sarcomas are a rare malignant subgroup of soft tissue sarcomas (STSs). STSs, accounting for 1% of all adult tumors, are derived from mesenchymal tissues and exhibit a wide heterogeneity. Their rarity and the high number of histotypes hinder the understanding of tumor development mechanisms and negatively influence clinical outcomes and treatment approaches. Although some STSs (~20%) have identifiable genetic markers, as specific mutations or translocations, most are characterized by complex genomic profiles. Thus, identification of new therapeutic targets and development of personaliz
Style APA, Harvard, Vancouver, ISO itp.
5

Roosen, Mieke, Chris Meulenbroeks, Phylicia Stathi, et al. "BIOL-11. PRECLINICAL MODELLING OF PEDIATRIC BRAIN TUMORS USING ORGANOID TECHNOLOGY." Neuro-Oncology 25, Supplement_1 (2023): i8. http://dx.doi.org/10.1093/neuonc/noad073.030.

Pełny tekst źródła
Streszczenie:
Abstract Molecular characterization has resulted in improved classification of pediatric brain tumors, leading to many novel (sub)types with distinct oncodriving events. To study tumor biology and to perform translational research on each of these tumors, preclinical models are essential. However, we are currently lacking sufficient models, especially in vitro, to represent each (sub)type and their heterogeneity. To generate large series of preclinical in vitro models for pediatric brain tumors, we are using organoid technology. Cells from patient samples and patient-derived xenograft samples
Style APA, Harvard, Vancouver, ISO itp.
6

Sewduth, Raj N., and Konstantina Georgelou. "Relevance of Carcinogen-Induced Preclinical Cancer Models." Journal of Xenobiotics 14, no. 1 (2024): 96–109. http://dx.doi.org/10.3390/jox14010006.

Pełny tekst źródła
Streszczenie:
Chemical agents can cause cancer in animals by damaging their DNA, mutating their genes, and modifying their epigenetic signatures. Carcinogen-induced preclinical cancer models are useful for understanding carcinogen-induced human cancers, as they can reproduce the diversity and complexity of tumor types, as well as the interactions with the host environment. However, these models also have some drawbacks that limit their applicability and validity. For instance, some chemicals may be more effective or toxic in animals than in humans, and the tumors may differ in their genetics and phenotypes.
Style APA, Harvard, Vancouver, ISO itp.
7

Ortiz, Michael Vincent, Armaan Siddiquee, Daoqi You, et al. "Preclinical evaluation of XPO1 inhibition in Wilms tumors." Journal of Clinical Oncology 38, no. 15_suppl (2020): 3580. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3580.

Pełny tekst źródła
Streszczenie:
3580 Background: XPO1 is a nuclear export protein that selectively transports tumor and growth regulatory proteins out of the nucleus, thereby effectively inhibiting their function. We previously utilized the Virtual Inference of Protein-activity by Enriched Regulon analysis (VIPER) algorithm to discover that malignant rhabdoid tumors were dependent upon XPO1 inhibition and then evaluated a preclinical cohort using selinexor (KPT-330), the first-in-class selective inhibitor of nuclear export, to demonstrate that XPO1 inhibition was sufficient to cause cell cycle arrest, apoptosis, and disease
Style APA, Harvard, Vancouver, ISO itp.
8

Sitta, Juliana, Pier Paolo Claudio, and Candace M. Howard. "Virus-Based Immuno-Oncology Models." Biomedicines 10, no. 6 (2022): 1441. http://dx.doi.org/10.3390/biomedicines10061441.

Pełny tekst źródła
Streszczenie:
Immunotherapy has been extensively explored in recent years with encouraging results in selected types of cancer. Such success aroused interest in the expansion of such indications, requiring a deep understanding of the complex role of the immune system in carcinogenesis. The definition of hot vs. cold tumors and the role of the tumor microenvironment enlightened the once obscure understanding of low response rates of solid tumors to immune check point inhibitors. Although the major scope found in the literature focuses on the T cell modulation, the innate immune system is also a promising onc
Style APA, Harvard, Vancouver, ISO itp.
9

Bella, Ángela, Claudia Augusta Di Trani, Myriam Fernández-Sendin, et al. "Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications." Cancers 13, no. 5 (2021): 963. http://dx.doi.org/10.3390/cancers13050963.

Pełny tekst źródła
Streszczenie:
Peritoneal carcinomatosis of primary tumors originating in gastrointestinal (e.g., colorectal cancer, gastric cancer) or gynecologic (e.g., ovarian cancer) malignancies is a widespread type of tumor dissemination in the peritoneal cavity for which few therapeutic options are available. Therefore, reliable preclinical models are crucial for research and development of efficacious treatments for this condition. To date, a number of animal models have attempted to reproduce as accurately as possible the complexity of the tumor microenvironment of human peritoneal carcinomatosis. These include: Sy
Style APA, Harvard, Vancouver, ISO itp.
10

Stripay, Jennifer L., Thomas E. Merchant, Martine F. Roussel, and Christopher L. Tinkle. "Preclinical Models of Craniospinal Irradiation for Medulloblastoma." Cancers 12, no. 1 (2020): 133. http://dx.doi.org/10.3390/cancers12010133.

Pełny tekst źródła
Streszczenie:
Medulloblastoma is an embryonal tumor that shows a predilection for distant metastatic spread and leptomeningeal seeding. For most patients, optimal management of medulloblastoma includes maximum safe resection followed by adjuvant craniospinal irradiation (CSI) and chemotherapy. Although CSI is crucial in treating medulloblastoma, the realization that medulloblastoma is a heterogeneous disease comprising four distinct molecular subgroups (wingless [WNT], sonic hedgehog [SHH], Group 3 [G3], and Group 4 [G4]) with distinct clinical characteristics and prognoses has refocused efforts to better d
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Rozprawy doktorskie na temat "Preclinical tumor models"

1

MINOLI, LUCIA. "TUMOR MICROENVIRONMENT IN EXPERIMENTAL PRECLINICAL MOUSE MODELS OF HUMAN CANCER: MORPHOLOGICAL APPROACH." Doctoral thesis, Università degli Studi di Milano, 2020. http://hdl.handle.net/2434/704551.

Pełny tekst źródła
Streszczenie:
One of the recent advancements in oncological research has been the recognition of the tumor microenvironment (TME) as a relevant participant during all stages of the evolution of a neoplastic process. Indeed, over the past decades, tumors have been considered through a changing perspective: no longer as a growth of homogeneous neoplastic cells, but as an actual organ composed of different cell populations and structures: the parenchyma being the neoplastic population and the stroma, including the vascular network and infiltrating cells. The tumor microenvironment has a dual role in tumor biol
Style APA, Harvard, Vancouver, ISO itp.
2

Chen, Liu Qi. "Development and Application of AcidoCEST MRI for Evaluating Tumor Acidosis in Pre-Clinical Cancer Models." Diss., The University of Arizona, 2014. http://hdl.handle.net/10150/323450.

Pełny tekst źródła
Streszczenie:
Tumor acidosis is an important biomarker in cancer. We have developed a noninvasive imaging method, termed acidosis Chemical Exchange Saturation Transfer (acidoCEST) MRI to measure extracellular pH (pHe) in the tumor microenvironment. Chapter 1 introduces the importance of measuring tumor acidosis and presents various imaging modalities and their shortcoming to measure pHe. Chapter 2 describes the optimization of acidoCEST MRI for in vivo pHe measurement. The acidoCEST MRI protocol consists of a CEST-FISP acquisition and Lorentzian line shape fittings. We determined the optimal saturation time
Style APA, Harvard, Vancouver, ISO itp.
3

Denton, Nicholas Lee Denton. "Modulation of tumor associated macrophages enhances oncolytic herpes virotherapy in preclinical models of Ewing sarcoma." The Ohio State University, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=osu1523892800897524.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

TOSCA, ELENA MARIA. "Dynamic energy budget based models of tumor-in-host growth inhibition and cachexia onset in preclinical settings." Doctoral thesis, Università degli studi di Pavia, 2019. http://hdl.handle.net/11571/1242427.

Pełny tekst źródła
Streszczenie:
Il processo di sviluppo di un nuovo farmaco oncologico e' caratterizzato da un elevatissimo numero di fallimenti, principalmente dovuti alla scarsa efficacia o eccessiva tossicita' riscontrata durante le fasi di sperimentazione clinica. Tra le possibili cause di questo fenomeno vi sono l'utilizzo di modelli animali poco rappresentativi della condizione umana e la mancanza di un paradigma di traslazione dal contesto preclinico a quello clinico sufficientemente predittivo. L'utilizzo di modelli farmacometrici, capaci di estrapolare, sintetizzare e integrare le informazioni raccolte durante la sp
Style APA, Harvard, Vancouver, ISO itp.
5

Lahr, Christoph Alexander. "Tissue-engineering humanised bone sarcoma models in rodents-a preclinical study platform for orthopaedic research." Thesis, Queensland University of Technology, 2021. https://eprints.qut.edu.au/207759/1/Christoph%20Alexander_Lahr_Thesis.pdf.

Pełny tekst źródła
Streszczenie:
This thesis is a step forward in preclinical in-vivo disease modelling, designed to find new diagnostic and therapeutic options, to ultimately improve the poor outcome of patients with primary bone cancer. Combining the principles of tissue-engineering, 3D-printing and advanced gene editing techniques the preclinical animal models developed in this thesis have important clinical implications that could shape future innovative treatment plans. Particularly the translation of a humanised osteosarcoma model from a mouse into a newly engineered severely immunocompromised rat will facilitate precli
Style APA, Harvard, Vancouver, ISO itp.
6

Laranga, Roberta <1985&gt. "Development of Preclinical Models of Mammary Carcinogenesis: Functional Role of Her2 and its Isoforms in Tumor Progression and in Drug Resistance." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2017. http://amsdottorato.unibo.it/7832/1/Laranga_Roberta_Tesi.pdf.

Pełny tekst źródła
Streszczenie:
Overexpression of huHER2 occurs in nearly 15–20% of breast cancers, and it is generally associated with poor patient survival. Existing therapies such as trastuzumab and lapatinib are currently used in the treatment of HER2-positive cancers, although issues with high recurrence and acquired resistance still remain. Elucidation of the molecular mechanisms underlying resistance is leading to the identification of therapies and strategies to manage resistance to HER2-targeted therapies. In addition to intrinsic and acquired resistance associated to HER2 oncogene, the induction of bypass pathways
Style APA, Harvard, Vancouver, ISO itp.
7

Fuchs, Jeannette [Verfasser], and Thorsten [Akademischer Betreuer] Stiewe. "Establishment and characterization of preclinical mouse models for evaluation of oncogenic and tumor-suppressive properties of p53 family members / Jeannette Fuchs ; Betreuer: Thorsten Stiewe." Marburg : Philipps-Universität Marburg, 2017. http://d-nb.info/1131253272/34.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Ferreira, Luís Pedro Correia Pinto. "Development of multicelular 3D cancer testing platforms for evaluation of new anti-cancer therapies." Master's thesis, Universidade de Aveiro, 2017. http://hdl.handle.net/10773/22713.

Pełny tekst źródła
Streszczenie:
Mestrado em Bioquímica Clínica<br>O cancro do pulmão (CP) é um dos cancros mais diagnosticados a nível mundial e também um dos mais mortíferos. Atualmente, as terapias administradas a nível clínico para o tratamento do CP são ainda extremamente ineficazes e limitadas no que diz respeito ao aumento da taxa de sobrevivência dos pacientes oncológicos. Esta realidade demonstra a necessidade de investigar ativamente novas terapias para o tratamento desta neoplasia. No entanto a validação pré-clínica de terapias inovadoras para o CP tem-se revelado extremamente difícil devido à inexistência de plat
Style APA, Harvard, Vancouver, ISO itp.
9

Wolska-Krawczyk, Malgorzata [Verfasser], and Arno [Akademischer Betreuer] Bücker. "Evaluation of liver tumor perfusion by intraarterial transcatheder magnetic resonance angiography during transarterial chemoembolization in patients with hepatocellular carcinoma : Preclinical instrument validation in vascular models and clinical study / Malgorzata Wolska-Krawczyk. Betreuer: Arno Bücker." Saarbrücken : Saarländische Universitäts- und Landesbibliothek, 2014. http://d-nb.info/1056906979/34.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Dobosz, Michael [Verfasser], Vasilis [Akademischer Betreuer] Ntziachristos, and Hans-Jürgen [Akademischer Betreuer] Wester. "The application of in vivo and ex vivo multispectral epi-fluorescence imaging for the preclinical discovery and development of monoclonal antibodies in tumor xenograft models / Michael Dobosz. Betreuer: Vasilis Ntziachristos. Gutachter: Hans-Jürgen Wester ; Vasilis Ntziachristos." München : Universitätsbibliothek der TU München, 2014. http://d-nb.info/1080903682/34.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Książki na temat "Preclinical tumor models"

1

Fiebig, H. H. Revelance Of Tumor Models For Anticancer Drug Development (CONTRIBUTIONS TO ONCOLOGY). Edited by H. H. Fiebig. Karger, 1999.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Powell, Craig M. PTEN and Autism With Macrocepaly. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199744312.003.0010.

Pełny tekst źródła
Streszczenie:
Phosphatase and Tensin homolog deleted on chromosome 10 (PTEN) is a gene encoding an intracellular signaling molecule. PTEN was originally discovered as the gene responsible for a subset of familial hamartoma (tumor) syndromes associated with increased risk for certain cancers (Nelen et al., 1997) and as a gene often mutated in human cancers and tumor cell lines (Li et al., 1997; Steck et al., 1997). More recently, mutations in PTEN have been linked genetically to the clinical phenotype of autism or developmental delay with macrocephaly (Boccone et al., 2006; Butler et al., 2005; Buxbaum et al
Style APA, Harvard, Vancouver, ISO itp.

Części książek na temat "Preclinical tumor models"

1

Teicher, Beverly A. "Preclinical Tumor Response End Points." In Tumor Models in Cancer Research. Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-968-0_23.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Morton, Christopher L., and Peter J. Houghton. "The Pediatric Preclinical Testing Program." In Tumor Models in Cancer Research. Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-968-0_8.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Gerner, Eugene W., Natalia A. Ignatenko, and David G. Besselsen. "Preclinical Models for Chemoprevention of Colon Cancer." In Tumor Prevention and Genetics. Springer Berlin Heidelberg, 2003. http://dx.doi.org/10.1007/978-3-642-55647-0_6.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Boss, Mary-Keara, Gregory M. Palmer, and Mark W. Dewhirst. "Imaging the Hypoxic Tumor Microenvironment in Preclinical Models." In Hypoxia and Cancer. Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-9167-5_7.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Nathanson, S. David. "Preclinical Models of Regional Lymph Node Tumor Metastasis." In Cancer Metastasis And The Lymphovascular System: Basis For Rational Therapy. Springer US, 2007. http://dx.doi.org/10.1007/978-0-387-69219-7_10.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Hillman, Gilda G. "Experimental Animal Models for Investigating Renal Cell Carcinoma Pathogenesis and Preclinical Therapeutic Approaches." In Tumor Models in Cancer Research. Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-968-0_12.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Sadekar, Shraddha, Isabel Figueroa, and Harish Shankaran. "Evaluation of Tumor Growth Inhibition in Preclinical Tumor Models: A Quantitative Approach." In Development of Antibody-Based Therapeutics. Springer Singapore, 2018. http://dx.doi.org/10.1007/978-981-13-0496-5_8.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Parchment, Ralph E. "Bone Marrow as a Critical Normal Tissue that Limits Drug Dose/Exposure in Preclinical Models and the Clinic." In Tumor Models in Cancer Research. Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-968-0_21.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Chambers, Ann F., Eva A. Turley, John Lewis, and Leonard G. Luyt. "Preclinical Cell and Tumor Models for Evaluating Radiopharmaceuticals in Oncology." In Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer. John Wiley & Sons, Inc., 2010. http://dx.doi.org/10.1002/9780470613214.ch11.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Jacoberger-Foissac, Celia, Bertrand Allard, David Allard, and John Stagg. "Assessing the Efficacy of Immune Checkpoint Inhibitors in Preclinical Tumor Models." In Methods in Molecular Biology. Springer US, 2023. http://dx.doi.org/10.1007/978-1-0716-2914-7_11.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Streszczenia konferencji na temat "Preclinical tumor models"

1

Joachim, Anais, Marielle Mello, Emilie Maturin, et al. "879 Deep immunoprofiling of tumor mouse models for preclinical studies." In SITC 39th Annual Meeting (SITC 2024) Abstracts. BMJ Publishing Group Ltd, 2024. http://dx.doi.org/10.1136/jitc-2024-sitc2024.0879.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Bagley, Rebecca G., Yi Ren, Leslie Kurtzberg, William Weber, Dinesh Bangari, and Beverly A. Teicher. "Abstract 1596: Human choriocarcinomas: Placental growth factor-dependent preclinical tumor models." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-1596.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Faia, Kerrie, Alberto Toso, Kristina Fetalvero, et al. "Abstract 1717: MAP4K1 inhibition enhances immune cell activation and anti-tumor immunity in preclinical tumor models." In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-1717.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Welm, Alana L. "Abstract IA07: Breast tumor grafts as preclinical models for anti-metastasis therapy." In Abstracts: AACR Special Conference on Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications - October 3-6, 2013; San Diego, CA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1557-3125.advbc-ia07.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Doody, Jacqueline, Sneha Mathew, Lan Wu, et al. "Abstract 3539: Anti-CSF-1R antibodies reduce tumor-associated macrophages and inhibit tumor growth in preclinical models." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-3539.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Li, Yanxia, Sneha Mathew, Lan Wu, et al. "Abstract C224: Anti-CSF-1R antibodies reduce tumor-associated macrophages and inhibit tumor growth in preclinical models." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 12-16, 2011; San Francisco, CA. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1535-7163.targ-11-c224.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Li, Yanxia, Sneha Mathew, Lan Wu, et al. "Abstract A235: Anti-CSF-1R antibodies reduce tumor-associated macrophages and inhibit tumor growth in preclinical models." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013; Boston, MA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.targ-13-a235.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Staniszewska, Anna, Joshua Armenia, Matthew King, et al. "Abstract 967: Anti-tumor and immune effects of olaparib +/- anti-PD-L1 in preclinical BRCA1mut tumor models." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-967.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Heuer, Timothy S., Richard Ventura, Joanna Waszczuk, et al. "Abstract 1815: Efficacy of FASN-selective small molecule inhibitors in preclinical tumor models." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-1815.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Sriram, Venkataraman, Michael E. Bigler, Holly Cherwinski, Erin Murphy, Terrill K. McClanahan, and Joseph H. Phillips. "Abstract 5025: Dissecting the dynamics of anti-PD1 immunotherapy in preclinical tumor models." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-5025.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Możesz być także zainteresowany rozszerzonymi bibliografiami na temat „Preclinical tumor models” dla poszczególnych typów źródeł:
Artykuły w czasopismach Rozprawy doktorskie
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii